Latest approaches to treating atopic dermatitis

Chemical Immunology and Allergy

Volumn 96, Issue , 2012, Pages 132-140

  Paller, Amy S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; EMOLLIENT AGENT; ERGOCALCIFEROL; FLUTICASONE; HYPOCHLORITE SODIUM; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEINASE; STEROID; TACROLIMUS; BETAMETHASONE VALERATE; CERAMIDE; CHOLESTEROL; DESMOCOLLIN; DESMOGLEIN 1; FATTY ACID; FILAGGRIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 13; INTERLEUKIN 4; KALLIKREIN 5; LACTOBIONIC ACID; LORICRIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PROFILAGGRIN; PROTEINASE ACTIVATED RECEPTOR 2; PSEUDOMONIC ACID; THYMIC STROMAL LYMPHOPOIETIN;

ADD ON THERAPY; ARTICLE; ATOPIC DERMATITIS; CONTACT DERMATITIS; DISEASE SEVERITY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PATIENT COMPLIANCE; PHOTOTHERAPY; PRIORITY JOURNAL; SKIN INFLAMMATION; STAPHYLOCOCCUS INFECTION; UNITED STATES; UNSPECIFIED SIDE EFFECT; WATER LOSS; BATH; MEDICATION COMPLIANCE; PERMEABILITY BARRIER; SKIN BARRIER; SKIN WATER LOSS; STAPHYLOCOCCUS AUREUS; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CHOLECALCIFEROL; CYTOKINES; DERMATITIS, ATOPIC; EMOLLIENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKINS; INTERMEDIATE FILAMENT PROTEINS; PEPTIDE HYDROLASES;

EID: 84859193708     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000331916     Document Type: Article

References (33)

1. Spergel JM, Paller AS: Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112: S118-S127.
2. Bieber T, Novak N: Pathogenesis of atopic dermatitis: New developments. Curr Allergy Asthma Rep 2009;9:291-294.
3. Elias PM, Steinhoff M: 'Outside-to-inside' (and now back to 'outside') pathogenic mechanisms in atopic dermatitis. J Invest Dermatol 2008;128:1067-1070.
4. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441-446.
5. van den Oord RA, Sheikh A: Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: Systematic review and metaanalysis. BMJ 2009;339:b2433.
6. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, Schneider L, Beck LA, Barnes KC, Leung DY: Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009;124:R7-R12.
7. Broccardo CJ, Mahaffey S, Schwarz J, Wruck L, David G, Schlievert PM, Reisdorph NA, Leung DY: Comparative proteomic profiling of patients with atopic dermatitis based on history of eczema herpeticum infection and Staphylococcus aureus colonization. J Allergy Clin Immunol 2011;127:186-193, 193.e181-111.
8. Voegeli R, Rawlings AV, Breternitz M, Doppler S, Schreier T, Fluhr JW: Increased stratum corneum serine protease activity in acute eczematous atopic skin. Br J Dermatol 2009;161:70-77.
9. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, Dubus P, Hovnanian A: Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009; 206:1135-1147.
10. Oyoshi MK, Larson RP, Ziegler SF, Geha RS: Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression. J Allergy Clin Immunol 2010;126:976-984, 984.e1-5.
11. Demehri S, Morimoto M, Holtzman MJ, Kopan R: Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol 2009;7:e1000067.
12. Imokawa G: A possible mechanism underlying the ceramide deficiency in atopic dermatitis: Expression of a deacylase enzyme that cleaves the N-acyl linkage of sphingomyelin and glucosylceramide. J Dermatol Sci 2009;55:1-9.
13. Ishikawa J, Narita H, Kondo N, Hotta M, Takagi Y, Masukawa Y, Kitahara T, Takema Y, Koyano S, Yamazaki S, Hatamochi A: Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatol 2010;130:2511-2514.
14. Jungersted JM, Scheer H, Mempel M, Baurecht H, Cifuentes L, Hogh JK, Hellgren LI, Jemec GB, Agner T, Weidinger S: Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy 2010;65:911-918.
15. Hatano Y, Man MQ, Uchida Y, Crumrine D, Scharschmidt TC, Kim EG, Mauro TM, Feingold KR, Elias PM, Holleran WM: Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitis. J Invest Dermatol 2009; 129:1824-1835.
16. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151-1160.
17. Kozman A, Yao Y, Bina P, Saha C, Yao W, Kaplan MH, Travers JB: Encoding a superantigen by Staphylococcus aureus does not affect clinical characteristics of infected atopic dermatitis lesions. Br J Dermatol 2010;163:1308-1311.
18. Travers JB, Kozman A, Mousdicas N, Saha C, Landis M, Al-Hassani M, Yao W, Yao Y, Hyatt AM, Sheehan MP, Haggstrom AN, Kaplan MH: Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid. J Allergy Clin Immunol 2010; 125:146-152.e1-2.
19. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC: Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev 2008:CD003871.
20. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS: Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009;123:e808-e814.
21. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:3262-3269.
22. Hata TR, Kotol P, Jackson M, Nguyen M, Paik A, Udall D, Kanada K, Yamasaki K, Alexandrescu D, Gallo RL: Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol 2008;122:829-831.
23. Li M, Hener P, Zhang Z, Ganti KP, Metzger D, Chambon P: Induction of thymic stromal lymphopoietin expression in keratinocytes is necessary for generating an atopic dermatitis upon application of the active vitamin D3 analogue MC903 on mouse skin. J Invest Dermatol 2009;129:498-502.
24. Sidbury R, Sullivan AF, Thadhani RI, Camargo CA Jr: Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: A pilot study. Br J Dermatol 2008;159: 245-247.
25. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R, Ward SJ: Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009;129: 1892-1908.
26. Jensen JM, Pfeiffer S, Witt M, Brautigam M, Neumann C, Weichenthal M, Schwarz T, Folster-Holst R, Proksch E: Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009;123:1124-1133.
27. Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL: Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: A new paradigm for use. Pediatrics 2008;122: E1210-e1218.
28. Breneman D, Fleischer AB Jr, Abramovits W, Zeichner J, Gold MH, Kirsner RS, Shull TF, Crowe AW, Jaracz E, Hanifin JM: Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: A randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008; 58:990-999.
29. Margolis DJ, Hoffstad O, Bilker W: Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214:289-295.
30. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127:808-816.
31. Arana A, Wentworth CE, Fernandez-Vidaurre C, Schlienger RG, Conde E, Arellano FM: Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol 2010;163:1036-1043.
32. Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, Fleischer AB Jr: Balkrishnan R, Feldman SR: Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007;56:211-216.
33. Mailhol C, Lauwers-Cances V, Rance F, Paul C, Giordano-Labadie F: Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: A study in 641 children. Allergy 2009;64:801-806.